Crohn's disease: future anti–tumor necrosis factor therapies beyond infliximab
- 30 June 2004
- journal article
- review article
- Published by Elsevier in Gastroenterology Clinics of North America
- Vol. 33 (2) , 285-301
- https://doi.org/10.1016/j.gtc.2004.02.009
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shockThe Lancet, 1998
- Thalidomide in Crohn's diseaseThe Lancet, 1997
- Function and Activation of NF-kappaB in the Immune SystemAnnual Review of Immunology, 1994
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Activation of Coagulation after Administration of Tumor Necrosis Factor to Normal SubjectsNew England Journal of Medicine, 1990
- Treatment of ulcerative colitis with thalidomide.BMJ, 1979